丙戊酸钠联合奥卡西平治疗癫痫对患者炎性因子及疗效的影响

To investigate the effect of sodium valproate combined with oxcarbazepine on inflammatory factors and efficacy in patients with epilepsy

目的探讨丙戊酸钠联合奥卡西平治疗癫痫的疗效及其对患者炎性因子的影响。方法选择2022年1月—2023年1月医院接收的100例癫痫患者进行研究,电脑随机编号奇偶数分为两组各50例,对照组采取丙戊酸钠治疗,观察组采取丙戊酸钠联合奥卡西平治疗,评价并比较两组治疗效果、神经因子、炎症因子、免疫功能、认知功能及生活质量,观察不良反应发生率。结果观察组和对照组的治疗有效分别为47例(94.00%)、39例(78.00%),观察组治疗有效率高于对照组(χ^(2)=5.315,P=0.02)。治疗后,观察组的脑源性神经营养因子(195.33±18.29)pg/mL、神经生长因子(594.69±54.45)ng/mL水平高,肿瘤坏死因子-α(4.12±1.07)pg/mL、IL-1β(3.48±0.79)pg/mL、IL-6(53.44±3.63)pg/mL水平比对照组(150.68±15.27)pg/mL、(542.46±45.56)ng/mL、(6.35±1.27)pg/mL、(4.35±0.93)pg/mL、(63.02±3.81)pg/mL低(t=13.250、5.201、9.495、5.041、12.872,P<0.05)。治疗后,观察组的IgM(1.02±0.12)g/L、IgG(10.02±1.22)g/L、IgA(2.10±0.22)g/L比对照组(1.13±0.14)g/L、(11.68±1.57)g/L、(2.65±0.31)g/L更高(t=4.218、5.903、10.230,P<0.05)。治疗后,观察组的蒙特利尔认知量表(27.78±2.15)分、日常生活活动量表(71.88±6.45)分、癫痫患者生活质量评定量表-31(82.65±8.25)分比对照组(25.33±2.01)分、(65.65±5.54)分、(74.05±7.37)分更高(t=5.886、5.181、5.497,P<0.05)。观察组、对照组发生不良反应组间比较差异无统计学意义(χ^(2)=1.010,0.343,1.010,1.010,1.010,P均>0.05)。结论丙戊酸钠联合奥卡西平治疗癫痫患者可取得良好的疗效,控制癫痫症状,改善神经因子、认知功能,增强免疫功能,控制炎症因子,而且不良反应少,利于生活质量提高。

Objective To investigate the effect of sodium valproate combined with oxcarbazepine in the treatment of epilepsy and its influence on inflammatory factors.Methods From January 2022 to January 2023,100 patients with epilepsy admitted to our hospital were selected and randomly divided into two groups,50 cases in each group.The control group was treated with sodium valproate,and the observation group was treated with sodium valproate combined with oxcarbazepine.The therapeutic effect,neurological factors,inflammatory factors,immune function,cognitive function and quality of life were evaluated and compared between the two groups,and the incidence of adverse reactions was observed.Results The effective rate of the observation group and the control group were 94.00%(47 cases)and 78.00%(39 cases),respectively.The effective rate of the observation group was higher than that of the control group(χ^(2)=5.315,P=0.02).After treatment,the levels of brain-derived neurotrophic factor(195.33±18.29)pg/mL and nerve growth factor(594.69±54.45)ng/mL in the observation group were higher than those in the control group.The levels of tumor necrosis factor-α(4.12±1.07)pg/mL,IL-1β(3.48±0.79)pg/mL,IL-6(53.44±3.63)pg/mL in the control group were(150.68±15.27)pg/mL,(542.46±45.56)ng/mL,(6.35±1.27)pg/mL,(4.35±0.93)pg/mL,(63.02±3.81)pg/mL(t=13.250,5.201,9.495,5.041,12.872,P<0.05).After treatment,the IgM(1.02±0.12)g/L,IgG(10.02±1.22)g/L,IgA(2.10±0.22)g/L were higher than those in the control group(1.13±0.14)g/L,(11.68±1.57)g/L,(2.65±0.31)g/L(t=4.218,5.903,10.230,P<0.05).After treatment,the scores of Montreal Cognitive Scale(27.78±2.15),Activities of Daily Living Scale(71.88±6.45)and Quality of Life in Epilepsy Scale 31(82.65±8.25)in the observation group were higher than those in the control group(25.33±2.01),(65.65±5.54)and(74.05±7.37)(t=5.886,5.181,5.497,P<0.05).There was no significant difference in adverse reactions between the observation group and the control group(χ^(2)=1.010,0.343,1.010,1.010,1.010,all P>0.05).Conclusions Sodium valproate combined with oxcarbazepine in the treatment of patients with epilepsy can achieve good curative effect,control epilepsy symptoms,improve neurological factors,cognitive function,enhance immune function,control inflammatory factors,with less adverse reactions,conducive to improve the quality of life.